Gyre Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-14.3M | $-18.6M | $5.9M | $-2.2M | $4.9M | $2.9M | $4.5M | $9.9M |
| Depreciation & Amortization | — | $672.0K | — | — | $535.0K | — | — | $415.0K |
| Depreciation | $1.1M | — | — | $800.0K | — | — | — | — |
| Amortization | $179.0K | $175.0K | $170.0K | $167.0K | $67.0K | $10.0K | $8.5K | $100.0K |
| Stock-Based Compensation | — | $2.6M | — | — | $507.0K | — | — | $11.0K |
| Net Cash from Operating Activities | $-16.7M | $3.2M | $14.2M | $-7.5M | $-129.0K | $1.7M | $-5.5M | $2.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $262.0K | $178.0K | $589.0K | $335.0K | $122.0K | $693.0K | $1.5M | $231.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $-3.1M | — | — | $2.0M | — | — | $-7.2M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $21.0K | — | — | $1.3M | — | — | $658.0K |
| Net Change in Cash | — | $431.0K | — | — | $3.2M | — | — | $-3.7M |
| Free Cash Flow | $-17.0M | $3.0M | $13.6M | $-7.8M | $-251.0K | $1.0M | $-6.9M | $2.7M |